C-Bridge Capital

C-Bridge Capital appeared to be the VC, which was created in 2014. The fund was located in Asia if to be more exact in China. The main department of described VC is located in the Shanghai.

The overall number of key employees were 11.

The standard case for the fund is to invest in rounds with 3-4 partakers. Despite the C-Bridge Capital, startups are often financed by Thomas, McNerney & Partners, Tasly Pharmaceutical, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Tasly Pharmaceutical, Qianhai Fund of Funds, WTT Investment. In the next rounds fund is usually obtained by Tasly Pharmaceutical, Xiamen Venture Capital, WTT Investment.

Opposing the other organizations, this C-Bridge Capital works on 12 percentage points less the average amount of lead investments. The higher amount of exits for fund were in 2018. When the investment is from C-Bridge Capital the average startup value is 100-500 millions dollars. Speaking about the real fund results, this VC is 47 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The usual things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually.

Among the most popular portfolio startups of the fund, we may highlight Ascletis, I-Mab Biopharma, CMAB BioPharm. The fund has specific favorite in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most successful fund investment fields, there are Medical, Product Research. Besides, a startup needs to be aged 4-5 years to get the investment from the fund.

Notable deals

Review

• No reviews are submitted yet.